Mankind Pharma Ltd (MANKIND) — Corporate Action | 1 September 2026

· BSE 🔴 High Importance Neutral
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings
📢 Key Event
Allotment of 49,112 shares under ESOP 2022
🔄 What Changed
Paid-up capital increased from 41,29,95,978 to 41,30,45,090 shares
💡 Investor Takeaway
This small ESOP issuance slightly dilutes existing shareholders' ownership without changing capital structure or providing growth guidance.

Mankind Pharma allotted 49,112 equity shares under its 2022 Employee Stock Option Plan on September 1, 2026, increasing paid-up capital from 41,29,95,978 to 41,30,45,090 shares at ₹1 face value. The shares carry a ₹860 exercise price and ₹859 premium, and rank pari-passu with existing shares.

📄 View Original Announcement (PDF)

About Mankind Pharma Ltd (MANKIND)

Healthcare · Pharmaceuticals · Listed on BSE

Market Cap: ₹97,467.05 Cr P/E: 47.7 ROE: 12.7% ROCE: 13.9% Div Yield: 0.04%

View full MANKIND stock details →

📡 Get AI alerts when MANKIND files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track MANKIND — Free

📊 More MANKIND filings

See all MANKIND filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when MANKIND files new disclosures

Track MANKIND filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track MANKIND — Free

Free account · 2 AI queries/day